Industry News (Joint Venture)

Agreement Entered for Potential Cancer Vaccine Platform Technology

Published in Vaccine Weekly, June 22nd, 1998

Select Therapeutics, Inc., Cambridge, Massachusetts, announced that it has entered into a Research and Exclusive Option Agreement with France's Institut Curie and the Centre National de la Recherche Scientfique (CNRS) regarding their intellectual property rights in the area of intracellular transport and targeted stimulation of immune response.

Under the agreement, Select Therapeutics provides financial support for the collaborative research at both the Institut Curie and the laboratory of Select Therapeutics' principal scientist, Dr. Cliff Lingwood, Research Institute of the Hospital for Sick Children in Toronto, Ontario, Canada. In return, Select Therapeutics...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1998-06-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry